Proposed Class Action Filed Against AbbVie Over Alleged Juvederm Granuloma Risks
A proposed class action lawsuit has been filed against AbbVie Inc., alleging that the pharmaceutical company failed to provide adequate warnings about the risk of granulomas and delayed-onset granulomas associated with certain Juvederm injectable dermal fillers. The case, Garcia v. AbbVie, Inc., Case No. 1:26-cv-07542, was filed on 27 June 2026 in the United States District Court for the Northern District of Illinois. The action is brought by California resident Christina Garcia on behalf of herself and proposed nationwide and California classes of Juvederm purchasers.
Juvederm is a range of hyaluronic acid-based injectable fillers used to address facial wrinkles, folds and volume loss. The complaint concerns Juvederm Ultra, Juvederm Ultra Plus and versions of those products containing lidocaine.
The lawsuit alleges that AbbVie’s product labelling, patient information and promotional materials did not adequately disclose that granulomas may develop following Juvederm treatment, including months or years after an injection. Granulomas are described in the complaint as concentrated areas of immune cells and inflammation that may present as hard, painful lumps beneath the skin.
According to the complaint, Garcia received several Juvederm facial injections in 2023 and paid for the procedures herself. She alleges that, in June 2026, she became seriously unwell as a result of delayed-onset granulomas and required hospitalisation and multiple medical procedures.
Garcia, who is identified in the complaint as a licensed pharmacist, claims she carefully reviewed the warnings supplied with the product. She alleges that she would not have undergone the treatments, or would have paid substantially less for them, had the possibility of granuloma and delayed-onset granuloma been adequately disclosed.
The complaint further alleges that AbbVie was aware of medical literature and post-market information concerning delayed inflammatory reactions but continued to market Juvederm without providing sufficiently prominent or detailed warnings about granulomas and their potential consequences.
These assertions are allegations made by the plaintiff and have not been determined by the court.
Garcia seeks to represent a nationwide class comprising people who purchased the Juvederm products during the relevant limitation periods, together with a proposed subclass of purchasers who allegedly developed granulomas or delayed-onset granulomas.
The action also proposes a separate California class covering people in California who purchased the products during the applicable period. Class-action status has been requested but has not yet been granted by the court.
The complaint brings claims including alleged violations of California’s Unfair Competition Law and Consumer Legal Remedies Act, as well as product-liability, failure-to-warn and unjust-enrichment claims.
Garcia is asking the court for relief including:
certification of the proposed classes;
actual and statutory damages;
restitution and disgorgement of profits;
an injunction requiring appropriate and accurate product representations and labelling;
legal costs, expenses and attorneys’ fees; and
any additional relief considered appropriate by the court.
The plaintiff has also demanded a jury trial. The case is being pursued by attorneys from Yagman PLLC and Reese LLP.
The allegations have not been proven in court, and AbbVie has not been found liable. A lawsuit may be filed by any individual or organisation, with or without legal representation. The filing of a complaint does not establish that the allegations are true or that the claimant will succeed. Court filings and class action lawsuits are generally matters of public record.
